Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2006-11-03
2011-10-18
Long, Scott (Department: 1633)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S145100, C424S130100, C514S002600, C514S04400A, C514S772000
Reexamination Certificate
active
08039010
ABSTRACT:
A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.
REFERENCES:
patent: 4521210 (1985-06-01), Wong
patent: 4853224 (1989-08-01), Wong
patent: 4997652 (1991-03-01), Wong
patent: 5164188 (1992-11-01), Wong
patent: 5443505 (1995-08-01), Wong
patent: 5501856 (1996-03-01), Ohtori
patent: 5766242 (1998-06-01), Wong
patent: 5824072 (1998-10-01), Wong
patent: 5869079 (1999-02-01), Wong
patent: 6074661 (2000-06-01), Olejnik
patent: 6248345 (2001-06-01), Goldenheim et al.
patent: 6331313 (2001-12-01), Wong
patent: 6369116 (2002-04-01), Wong
patent: 6699493 (2004-03-01), Wong
patent: 6713081 (2004-03-01), Robinson
patent: 6818447 (2004-11-01), Pavco
patent: 6899717 (2005-05-01), Weber
patent: 7048946 (2006-05-01), Wong
patent: 7090681 (2006-08-01), Weber
patent: 2004/0054374 (2004-03-01), Weber
patent: 2004/0138163 (2004-07-01), McSwiggen et al.
patent: 2004/0170665 (2004-09-01), Donovan
patent: 2005/0196421 (2005-09-01), Hunter et al.
patent: 2006/0020044 (2006-01-01), Berlin
patent: 2006/0121085 (2006-06-01), Warren et al.
patent: 2006/0182783 (2006-08-01), Hughes et al.
patent: 2006/0210604 (2006-09-01), Dadey et al.
patent: 2006/0216242 (2006-09-01), Rohloff et al.
patent: 2009/0226531 (2009-09-01), Lyons et al.
patent: 2009/0258924 (2009-10-01), Lyons et al.
patent: 2010/0311808 (2010-12-01), Lyons et al.
patent: WO 94/14417 (1994-07-01), None
patent: WO 95/35097 (1995-12-01), None
patent: WO 2004/081196 (2004-09-01), None
patent: WO 2006/041942 (2004-09-01), None
patent: WO 2005/110362 (2005-11-01), None
patent: WO 2006/053175 (2006-05-01), None
Van Wijngaarden et al. (JAMA. Mar. 23/30, 2005; 293(12): 1509-1513).
Stone et al (N Engl J Med. Oct. 5, 2006, 355(14): 1493-1495).
Boehringer-Ingelheim (Specification Sheets for RG-752; 2006; Inherent Viscosity and MW for RG-752).
Schwach et al (European Journal of Pharmaceutics and Biopharmaceutics. 2003; 56: 327-336).
Carrasquillo al (Investigative Opthalmology & Visual Science. Jan. 2003; 44(1): 290-299).
U.S. Appl. No. 10/917,909, filed Aug. 13, 2004, Weber.
U.S. Appl. No. 11/370,301, filed Mar. 8, 2006, Hughes.
U.S. Appl. No. 11/364,687, filed Feb. 27, 2006, Hughes.
U.S. Appl. No. 11/116,698, filed Apr. 27, 2005, Hughes.
U.S. Appl. No. 11/021,947, filed Dec. 23, 2004, Weber.
Carrasquillo K. et al.,Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres, IOVS Jan. 2003 44(1).
Gaudreault et al.,Preclinical pharmacokinetics of ranibizumab(rhuFabV2)after a single intravitreal administration, IOVS, (2005); 46(2):726-733.
Heller, Biodegradable Polymers in Controlled Drug Delivery, In: CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, CRC Press, Boca Raton, FL 1987, pp. 39-90.
Jackson J. et al.,The encapsulation of ribozymes in biodegradable polymeric matrices, Int J of Pharmaceutics 243 (2002) 43-55.
Khan A. et al.,Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies, J Drug Target, Jul. 12, 2004(6), pp. 393-404.
Rosa G., et al.,A new delivery system for antisense therapy: PLGA microspheres encapsulating olignucleotide/polyethyleneimine solid complexes, Int J of Pharmaceutics 254 (2003) 89-93.
Lyons Robert T.
Trogden John T.
Allergan Inc.
Condino Debra D.
German Joel B.
Long Scott
Wollenberge Louis V.
LandOfFree
Sustained release intraocular drug delivery systems... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release intraocular drug delivery systems..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release intraocular drug delivery systems... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4274404